Visual and Refractive Outcomes After Bilateral Implantation of a New Toric Intraocular Lens.

PURPOSE

To evaluate the clinical outcomes of a new FDA approved toric aspheric hydrophobic acrylic intraocular lens.

PATIENTS AND METHODS

This is a single surgeon, single-arm, on-label, non-randomized, prospective observational study. Thirty patients underwent bilateral cataract surgery (60 eyes) with placement of a Clareon™ Toric IOL in each eye. The Barrett Universal II formula and Barrett toric calculator were used to determine the IOL power and toric axis. Endpoints included binocular and monocular best corrected distance visual acuity (BCDVA), binocular and monocular best uncorrected distance visual acuity (UCDVA), binocular uncorrected intermediate visual acuity (UCIVA), manifest refraction and patient Satisfaction Survey (IOLSAT) results over a 3 month follow-up.

RESULTS

The postoperative mean LogMAR visual acuity for binocular BCDVA and UCDVA were each 0.01±0.05. The monocular BCDVA and UCDVA were 0.04±0.06 and 0.08±0.08 respectively. The mean refractive cylinder improved from 1.87±1.12D to 0.43±0.25D with 78.3% within 0.50D. The mean refractive spherical equivalent (MRSE) was 0.008 ± 0.30 D (range -0.75 to +0.63, 93.3% results within ± 0.5D). Patient surveys showed 96.7% gained distance spectacle independence and 96.7% would recommend this lens to friends or family members.

CONCLUSION

The Clareon Monofocal Toric IOL is effective in astigmatism correction and significantly improved uncorrected distance visual acuity. High spectacle independence for distance vision and high overall satisfaction were achieved.